Diatrizoate Pregnancy and Breastfeeding Warnings
Brand names: Angiografin, Cardiografin, Cystografin, Cystografin-Dilute, Gastrografin, Hypaque, Hypaque Cysto, Hypaque Meglumine, Hypaque Sodium, Hypaque-76, Hypaque-M, MD-76, MD-Gastroview, Reno-30, Reno-60, Reno-Dip, Reno-M-30, Reno-M-60, Reno-M-DIP, Renocal-76, Renografin-60, Renografin-76, Renovist, Renovist II, Urovison
Diatrizoate Pregnancy Warnings
AU: Use is contraindicated.
UK, US: Use is not recommended unless clearly needed.
AU TGA pregnancy category: Not assigned
US FDA pregnancy category: C
Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Adequate and well-controlled studies in pregnant women have not been conducted
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Diatrizoate Breastfeeding Warnings
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Yes
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
References for breastfeeding information
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.